Targeting of CD28 and CD38 as a potential novel therapeutic strategy for peripheral T-cell lymphomas
The identification of new targets and therapeutic strategies for peripheral T-cell lymphomas (PTCLs), which often have an aggressive clinical course, is needed. Bi and trispecific antibodies allowing ...
Chimeric Antigen Receptor T (CAR-T) cell therapy is a new type of cancer treatment that has shown great promise in treating blood cancers, such as B cell lymphomas and leukemias, and multiple myeloma.
MDX2003 targets CD19 and CD20 on B cells and CD3 and CD28 on T cells, enhancing antitumor activity and reducing antigen loss. The therapy's design limits cytokine release syndrome, showing improved ...
The chemokine (C-C motif) chemokine ligand 18 (CCL18) is a structural homolog of CCL3 primarily produced by monocyte-derived cells with an M2 phenotype. Elevated levels of CCL18 have been observed in ...
GMP ActiveMax ® Human T Cell Activation/Expansion CD3/CD28 Beads are uniform 5.5 μm magnetic beads coated with an optimized mixture of GMP-grade mouse monoclonal antibodies targeting CD3 and CD28, ...
Lamkap Bio Alpha AG's κλ bispecific antibodies include a κ light chain recognizing one target and a λ light chain recognizing a second target. The company has presented data showing the benefit of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results